Skip to main content
main-content

25.07.2017 | Original Article | Ausgabe 2/2018

International Journal of Diabetes in Developing Countries 2/2018

How good is procalcitonin as a marker in case of sepsis in diabetes mellitus?

Zeitschrift:
International Journal of Diabetes in Developing Countries > Ausgabe 2/2018
Autoren:
Pawan Sagar, Ashwani Kumar, S. V. Madhu, Bineeta Kashyap

Abstract

Prompt diagnosis and treatment with appropriate antimicrobial chemotherapy are of paramount importance to reduce morbidity and mortality associated with sepsis. The limitations of blood cultures have fostered interest in the development of sensitive and rapid laboratory biomarkers of sepsis. Procalcitonin has been proposed as a marker of disease severity in septicemia. The aim of the study was to assess the accuracy and clinical value of procalcitonin for diagnosis of sepsis in diabetes mellitus. A descriptive, cross-sectional study was conducted on 30 cases of known diabetes mellitus admitted in the Endocrinology I.C.U. with suspected bacterial infection and sepsis. The bacterial isolates were identified by standard protocol. A double-antibody sandwich enzyme-linked immunosorbent one-step process assay was used to assay the levels of procalcitonin. There was positive correlation between procalcitonin levels and the number of days for total leukocyte count to subside though duration of hospital stay or time taken for fever to subside was not significantly correlating. Positivity in blood culture was significantly correlating with median procalcitonin levels though C-reactive protein levels were unable to demonstrate the same. Other markers of severity of sepsis were not significantly correlating with procalcitonin levels. No glycemic marker showed any significant correlation with procalcitonin levels. With good clinical judgment and judicious use of antimicrobial agents, procalcitonin could serve as a valuable adjunct in the diagnosis and management of sepsis with diabetes mellitus. Search for more validated biomarkers should be emphasized upon.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

International Journal of Diabetes in Developing Countries 2/2018Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.